Marks Wealth’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
Other funds holding XBI
Marks Wealth's XBI Position: Q1 2026 in Review
Marks Wealth sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2026, closing a stake of 236,668 shares — an estimated $28.9M sold.
Marks Wealth first reported a position in XBI in Q4 2025 and held it in 1 quarter. The position peaked at $28.9M in Q4 2025. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.
- Marks Wealth reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2026 after selling out during the quarter.
- Marks Wealth sold 236,668 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $28.9M.
- Marks Wealth first reported a position in State Street SPDR S&P Biotech ETF in Q4 2025 and held it in 1 quarter.
- Marks Wealth's State Street SPDR S&P Biotech ETF position peaked at $28.9M in Q4 2025.
- 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.
Based on Marks Wealth's 13F filing for Q1 2026, filed 4 May 2026.